IFNL3 and diabetic kidney disease: Subjects with favourable outcomes showed higher circulating IFN-λ3, also after adjustment for age, duration of renal replacement therapy (RRT), low-flux HD, diabetic nephropathy, chronic glomerulonephritis, anuric status (daily urine output ≤ 100 mL), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT).